CRVS vs CTNM

Corvus Pharmaceuticals, Inc. vs Contineum Therapeutics, Inc. — Valuation Comparison 2026

CRVS

Biotechnology
Corvus Pharmaceuticals, Inc.
Quality
4.6
out of 10
Value Trap
18
SAFE
Price
$12.50
Last close
Models
7/13
Active
VS

CTNM

Biotechnology
Contineum Therapeutics, Inc.
Quality
4.6
out of 10
Value Trap
12
SAFE
Price
$13.31
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CRVS Fair ValueCRVS Upside CTNM Fair ValueCTNM Upside
Bayesian DCF Intrinsic $3.61 -71.1% $0.26 -98.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.51 -96.7% $4.05 -69.6%
Dynamic NAV Asset-Based $2.41 -80.7% $3.43 -74.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRVS vs CTNM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRVS vs CTNM — Which Stock Is More Undervalued?

CRVS scores higher with a 4.6/10 quality rating vs CTNM's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Corvus Pharmaceuticals, Inc. (CRVS) and Contineum Therapeutics, Inc. (CTNM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRVS currently trades at $12.50 with a QOC of 4.6/10, while CTNM trades at $13.31 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).